Zai Lab Total Assets 2016-2022 | ZLAB

Zai Lab total assets from 2016 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Zai Lab Annual Total Assets
(Millions of US $)
2021 $1,610
2020 $1,298
2019 $355
2018 $302
2017 $250
2016 $89
2015 $14
Zai Lab Quarterly Total Assets
(Millions of US $)
2022-03-31 $1,501
2021-12-31 $1,610
2021-09-30 $1,728
2021-06-30 $1,895
2021-03-31 $1,131
2020-12-31 $1,298
2020-09-30 $0
2020-03-31 $0
2019-12-31 $355
2019-09-30 $392
2019-06-30 $446
2018-12-31 $302
2017-12-31 $250
2017-06-30 $104
2016-12-31 $89
2015-12-31 $14
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.225B $0.144B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.746B 9.96
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.525B 16.61
Biohaven Pharmaceutical Holding (BHVN) United States $9.916B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.438B 6.15
Arcus Biosciences (RCUS) United States $1.419B 35.98
Myovant Sciences (MYOV) United Kingdom $0.944B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.492B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.309B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.085B 0.00